Compare MMYT & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MMYT | BLLN |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | India | United States |
| Employees | N/A | 713 |
| Industry | Transportation Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.9B |
| IPO Year | 2010 | N/A |
| Metric | MMYT | BLLN |
|---|---|---|
| Price | $41.03 | $102.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $101.00 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 858.5K | 735.1K |
| Earning Date | 05-20-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.83 | $46.29 |
| Revenue Next Year | $17.24 | $30.14 |
| P/E Ratio | $107.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.67 | $61.96 |
| 52 Week High | $104.99 | $138.70 |
| Indicator | MMYT | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 40.15 | 59.32 |
| Support Level | $39.07 | $79.07 |
| Resistance Level | $51.24 | $107.00 |
| Average True Range (ATR) | 2.35 | 7.98 |
| MACD | -0.29 | 0.71 |
| Stochastic Oscillator | 9.00 | 75.62 |
MakeMyTrip Ltd is an online travel company, which provides online booking solutions for day-to-day travel needs. The company's operating segment includes Air ticketing; Hotels and packages; Bus ticketing and Others. It generates maximum revenue from the Hotels and packages segment. The Hotels and packages segments include internet-based platforms, call-centers, and branch offices, which provide holiday packages and hotel reservations. Its Air ticketing segment includes internet-based platforms, provides the facility to book domestic and international air tickets. Geographically, it derives a majority of revenue from India and also has a presence in the United States; South East Asia; Europe, and other countries.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.